Researchers develop 'smart antibiotics' to combat C. diff

Researchers at State College-based Pennsylvania State University  and Tucson-based University of Arizona are developing smart antibiotics, which can target genes belonging to Clostridium difficile bacteria, according to a study published in The Journal of Antibiotics.

Traditional antibiotics wipe out all forms of bacteria, including the good bacteria found in patients' stomachs, which can help fight C. diff infections.

For the study, Arun Sharma, PhD, associate professor of pharmacology at the Penn State College of Medicine and David Stewart, MD, associate professor of surgery at the University of Arizona College of Medicine, created new forms of antibiotics, called antisense treatments in a laboratory setting. These "smart antibiotics" work in a completely different manner than other antibiotics currently in use.

"Our antisense antibiotics contain genetic material, which is complementary to bacterial genetic material, so we designed our genetic material to target specific genes in C. difficile," Dr. Stewart told Futurity. "And when our genetic material binds to the bacterial genetic material, it prevents the expression of bacterial genes. And that can cause C. difficile to die."

Researchers plan to conduct further studies to refine the antibiotic in preparation for animal testing.

More articles on clinical leadership and infection control:

Hospital staff don't always use infection prevention gear correctly, study finds

Ohio hospitals are facing a ban on nurse overtime — here's how it could affect patients

186 patients potentially exposed to HIV, hepatitis C at Oklahoma hospital

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Whitepapers

Featured Webinars